This study provides a new strategy for enhancing the activity of DEXs derived from patients with MM, with the potential to develop DEXs as an antitumor vaccine for MM.

P1, N=18, Not yet recruiting, Base Therapeutics (Shanghai) Co., Ltd.

P1, N=8, Terminated, Second Affiliated Hospital of Xi'an Jiaotong University | N=34 --> 8 | Not yet recruiting --> Terminated; Achieved the proof of concept

Pretreatment CD4+ T-cell levels were identified as a prognostic PFS marker. In summary, our results demonstrate significant effects of cycloaddition to Pd on response and T-cell composition.

P1/2, N=37, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting

P1, N=12, Recruiting, University of Michigan Rogel Cancer Center | Not yet recruiting --> Recruiting

When combined with standard agents such as daratumumab, pomalidomide, or cereblon E3 ligase modulatory drugs, forimtamig has shown improved tumor clearance and reduced relapse rates. Currently undergoing phase 1 trials, forimtamig is being evaluated both as monotherapy and in combination regimens. Its high potency, favorable safety, and durable immune engagement make it a promising candidate in the evolving treatment landscape of multiple myeloma.

P1/2, N=7, Terminated, Celularity Incorporated | N=86 --> 7 | Active, not recruiting --> Terminated; Lack of enrollment due to COVID treatment options availability.

P2, N=90, Recruiting, MiNK Therapeutics

P1, N=9, Recruiting, Zelluna Immunotherapy AS

P=N/A, N=30, Not yet recruiting, The First Affiliated Hospital of Soochow University

P1, N=32, Terminated, Sanofi | Phase classification: P1/2 --> P1